HMGA2 Polymorphisms and Hepatoblastoma Susceptibility: A Five-Center Case-Control Study

Background: Hepatoblastoma is a rare disease. Its etiology remains obscure. No epidemiological reports have assessed the relationship of High Mobility Group A2 (HMGA2) single nucleotide polymorphisms (SNPs) with hepatoblastoma risk. This case-control study leads as a pioneer to explore whether HMGA2 SNPs (rs6581658 A>G, rs8756 A>C, rs968697 T>C) could impact hepatoblastoma risk.

Methods: We acquired samples from 275 hepatoblastoma cases and 1018 controls who visited five independent hospitals located in the different regions of China. The genotyping of HMGA2 SNPs was implemented using the PCR-based TaqMan method, and the risk estimates were quantified by odds ratios (ORs) and 95% confidence intervals (CIs).

Results: In the main analysis, we identified that rs968697 T>C polymorphism was significantly related to hepatoblastoma risk in the additive model (adjusted OR=0.73, 95% CI=0.54–0.98, P=0.035). Notably, participants carrying 2–3 favorable genotypes had reduced hepatoblastoma risk (adjusted OR=0.71, 95% CI=0.52–0.96, P=0.028) in contrast to those carrying 0–1 favorable genotypes. Furthermore, stratification analysis revealed a significant correlation between rs968697 TC/CC and hepatoblastoma risk for males and clinical stage I+II. The existence of 2–3 protective genotypes was correlated with decreased hepatoblastoma susceptibility in children ≥17 months old, males, and clinical stage I+II cases, when compared to 0–1 protective genotype.

Conclusion: To summarize, these results indicated that the HMGA2 gene SNPs exert a weak influence on hepatoblastoma susceptibility. Further validation of the current conclusion with a larger sample size covering multi-ethnic groups is warranted.

Keywords: hepatoblastoma, HMGA2, polymorphism, susceptibility

Introduction

Hepatoblastoma is the most common form of pediatric liver malignancies. It takes up nearly 80% of all pediatric liver cancers. However, hepatoblastoma is a rare disease overall and constitutes just over 1% of all pediatric cancers. Most of the hepatoblastomas are originated from epithelium, primarily composed of immature hepatocytic elements. The 5-year overall survival (OS) in hepatoblastoma children is nearly 70%.

Unlike adult hepatocellular carcinoma, the etiology of hepatoblastoma remains obscure, due to its extreme rarity (1.1 per million for Chinese children). Hepatitis B virus, chronic hepatitis, and cirrhosis are causative factors for hepatocellular carcinoma rather than the hepatoblastoma. Accumulating data suggested several risk factors that might lead to hepatoblastoma including thrombocytosis, Beckwith-Wiedemann syndrome, fetal alcohol syndrome, hereditary adenomatous polyposis,
and glycogen storage disease. A few epidemiological reports have indicated that single nucleotide polymorphisms (SNPs) might also be predisposing factors for hepatoblastoma. However, it is difficult to obtain a significant association owing to the scarcity of included patients. Therefore, unveiling the underlying etiology of hepatoblastoma using a larger sample size, especially causative genetic factors, is of great significance.

HMGA2, short for High Mobility Group A2, pertains to the high mobility group family. HMGA2 is a non-histone nuclear-binding protein with three DNA binding domains, namely AT-hooks, short basic repeats, and terminal with an acidic carboxyl group. It can serve as an architectural transcription factor through interacting with the minor groove of A: T-abundant DNA fragments. As an oncofetal protein, HMGA2 is omnipresently expressed during embryogenesis. However, this protein rarely exists in differentiated cells and adult human tissues. HMGA2 acts as a critical regulator in the development of the embryo. It is noteworthy that the evidence of oncogenic activities of HMGA2 increasingly grows. Re-expression and amplification of HMGA2 were detected in a variety of cancers. Interestingly, intensive research has suggested a significant association between HMGA2 gene variants and childhood/adult heights. Recently, evidence has been published, supporting the impact of HMGA2 gene SNPs on uterine leiomyomata risk. However, the relevance of HMGA2 gene SNPs to hepatoblastoma risk has not been reported so far.

To shed light on this topic, we investigated the relationship of HMGA2 SNPs with the risk of hepatoblastoma using a set of 275 patients and 1018 controls enrolled from five unrelated medical centers. Our findings aid in understanding the etiology of hepatoblastoma.

Materials and Methods

Study Subjects

Children histologically verified with hepatoblastoma were enrolled from five independent hospitals (Guangzhou Women and Children’s Medical Center, the First Affiliated Hospital of Zhengzhou University, Shengjing Hospital of China Medical University, Kunming Children’s Hospital, Xijing Hospital) located at Guangdong, Henan, Liaoning, Yunnan, and Shaanxi provinces in China. Patients with multiple cancers and those who underwent chemotherapy or radiation were excluded from the study. The healthy controls without cancer hereditary history in the family were recruited from the same respective hospital as the cases. The cases and controls were comparable in age, sex, and non-relatives of each other. In total, 275 children with hepatoblastoma and 1018 matched controls were included in the current investigation. Each eligible subject’s parents or guardians signed written informed consent before the collection of patient samples and associated clinical data. A detailed description of subjects could be found in the previously published studies. The study protocol was permitted by the Ethics Committee of each participating hospital (Ethical approve number: 2017120101). This study was conducted in accordance with the Declaration of Helsinki.

Genotyping

SNPs were selected based on the published criteria. Genomic DNA extraction from subjects’ blood was performed utilizing a customized TIANamp Blood DNA Kit manufactured by TianGen Biotech Co. Ltd. (Beijing, China). SNP genotyping was conducted by PCR-based TaqMan methodology, as outlined in the manufacturer manual. Blinded fashion without knowing the status of samples was adopted to ensure genotyping accuracy. We also re-genotyped 10% randomly selected samples. A 100% concordance rate was achieved in the re-genotyped samples.

Statistical Analysis

All SNPs were tested for the Hardy-Weinberg equilibrium (HWE) separately in the controls using a χ² test. In cases and controls, the differences in clinical characteristics were determined by the adoption of a two-sided χ² test. The association of the SNP with hepatoblastoma risk was tested using multivariable logistic regression analysis with adjustment for age and gender. Multivariate logistic regression analysis was employed to generate odds ratios (ORs) for the associations, with 95% confidence intervals (CIs). P < 0.05 indicates differences were statistically significant between the groups. All P values are two-sided. The SAS 9.1 (SAS Institute, Cary, NC) was chosen to perform all statistical tests.

Results

Participant Characteristics

The clinical features of the study population are listed in Supplemental Table 1. We selected a total of 275 cases with an average age of 23.81 ± 25.82 months and 1018 healthy controls with an average age of 25.10 ± 19.35
months. Similar distributions between patients and control subjects were found, concerning age ($P=0.365$) and gender ($P=0.589$).

**Evaluation Association of SNPs with Hepatoblastoma Risk**

The association between the selected SNPs (rs6581658 A>G, rs8756 A>C, rs968697 T>C) and risk of hepatoblastoma was presented in Table 1. The distribution frequencies of the SNP genotypes of the control group were in accordance with HWE ($P>0.05$). Of the three SNPs, only SNP rs968697 T>C displayed a statistically significant association with hepatoblastoma risk under the additive model (adjusted OR=0.73, 95% CI=0.54–0.98, $P=0.035$). The rs6581658 GG, rs8756 AC/AA, and rs968697 TC/CC were then assumed as protective genotypes. Compared to the subjects with 0–1 protective genotype, the carriers of 2–3 favorable genotypes exhibited a lower probability of developing hepatoblastoma (adjusted OR=0.71, 95% CI=0.52–0.96, $P=0.028$).

**Stratification Analysis**

We then assessed the effects of the rs968697 genotype and the joint protective genotypes in stratification analyses by age (<17 months old vs ≥17 months old), gender (male vs female), and clinical stages (stage I+II vs III+IV) (Table 2). It was observed that rs968697 TC/CC genotypes were notably correlated with a decreased risk of hepatoblastoma in males (adjusted OR=0.64, 95% CI=0.42–0.98, $P=0.040$) and clinical stage I+II children (adjusted OR=0.63, 95% CI=0.41–0.98, $P=0.042$) diseases.

**Table 1** Association Between HMGA2 Gene Polymorphisms and Hepatoblastoma Risk

| Genotype      | Cases (N=275) | Controls (N=1018) | P<sup>a</sup> | Crude OR (95% CI) | Adjusted OR (95% CI)<sup>b</sup> | P<sup>b</sup> |
|--------------|---------------|-------------------|-------------|-------------------|-------------------------------|-------------|
| rs6581658 A>G (HWE=0.507) | | | | | | |
| AA           | 166 (60.36)   | 644 (63.26)       | 1.00        | 1.00              | 1.00                          | 1.00        |
| AG           | 99 (36.00)    | 327 (32.12)       | 1.18 (0.89–1.56) | 0.264              | 1.17 (0.88–1.56)             | 0.269       |
| GG           | 10 (3.64)     | 47 (4.62)         | 0.83 (0.41–1.67) | 0.593              | 0.82 (0.41–1.67)             | 0.591       |
| Additive     |               |                   | 0.624       | 1.06 (0.84–1.33)  | 0.624                        | 0.632       |
| Dominant     | 109 (39.64)   | 374 (36.74)       | 0.378       | 1.13 (0.86–1.49)  | 0.378                        | 0.385       |
| Recessive    | 265 (96.36)   | 971 (95.38)       | 0.482       | 0.78 (0.39–1.56)  | 0.483                        | 0.482       |

| rs8756 A>C (HWE=0.512) | | | | | | |
| AA           | 207 (75.27)   | 798 (78.39)       | 1.00        | 1.00              | 1.00                          | 1.00        |
| AC           | 64 (23.27)    | 209 (20.53)       | 1.18 (0.86–1.62) | 0.308              | 1.19 (0.86–1.63)             | 0.297       |
| CC           | 4 (1.45)      | 11 (1.08)         | 1.40 (0.44-4.45) | 0.566              | 1.39 (0.44-4.42)             | 0.575       |
| Additive     |               |                   | 0.254       | 1.18 (0.89–1.57)  | 0.254                        | 0.248       |
| Dominant     | 68 (24.73)    | 220 (21.61)       | 0.270       | 1.19 (0.87–1.63)  | 0.271                        | 0.262       |
| Recessive    | 271 (98.55)   | 1007 (98.92)      | 0.607       | 1.35 (0.43–4.28)  | 0.608                        | 0.618       |

| rs968697 T>C (HWE=0.896) | | | | | | |
| TT           | 216 (78.55)   | 743 (72.99)       | 1.00        | 1.00              | 1.00                          | 1.00        |
| TC           | 57 (20.73)    | 254 (24.95)       | 0.77 (0.56–1.07) | 0.118              | 0.77 (0.56–1.06)             | 0.112       |
| CC           | 2 (0.73)      | 21 (2.06)         | 0.33 (0.08–1.41) | 0.134              | 0.32 (0.08–1.40)             | 0.130       |
| Additive     |               |                   | 0.037       | 0.73 (0.54–0.98)  | 0.037                        | 0.73 (0.54–0.98) 0.035 |
| Dominant     | 59 (21.45)    | 275 (27.01)       | 0.062       | 0.74 (0.54–1.02)  | 0.062                        | 0.73 (0.53–1.01) 0.058 |
| Recessive    | 273 (99.27)   | 997 (97.94)       | 0.137       | 0.35 (0.08–1.49)  | 0.155                        | 0.35 (0.08–1.48) 0.152 |

| Combined effect of protective genotypes<sup>c</sup> | | | | | | |
| 0           | 1 (0.36)      | 5 (0.49)          | 1.00        | 1.48 (0.17–12.78) | 0.719                        | 1.49 (0.17–12.82) 0.718 |
| 1           | 209 (76.00)   | 704 (69.16)       | 1.06 (0.12–9.22) | 0.958              | 1.06 (0.12–9.22)             | 0.960       |
| 2           | 64 (23.27)    | 302 (29.67)       | 0.71 (0.04–14.35) | 0.826              | 0.71 (0.04–14.20)             | 0.820       |
| 3           | 1 (0.36)      | 7 (0.69)          | 1.00        | 1.00              | 1.00                          | 1.00        |
| 0–1         | 210 (76.36)   | 709 (69.65)       | 0.029       | 0.71 (0.52–0.97)  | 0.030                        | 0.71 (0.52–0.96) 0.028 |
| 2–3         | 65 (23.64)    | 309 (30.35)       | 1.00        | 1.00              | 1.00                          | 1.00        |

Notes: The values were in bold, if the 95% CI excluded 1 or $P$-value less than 0.05. *Adjusted for age and gender. **Risk genotypes were rs6581658 GG, rs8756 AC/AA and rs968697 TC/CC.

Abbreviations: OR, odds ratio; CI, confidence interval; HWE, Hardy-Weinberg equilibrium.
subgroups of age ≥17 months (adjusted OR=0.59, 95% CI=0.37–0.94, P=0.028), males (adjusted OR=0.62, 95% CI=0.41–0.94, P=0.023), and children in clinical stage I+II (adjusted OR=0.59, 95% CI=0.38–0.90, P=0.016) diseases, the existence of 2–3 protective genotypes was correlated with 0.59-fold, 0.62-fold and 0.59-fold decreased risk of hepatoblastoma, respectively, when compared to 0–1 protective genotypes.

Discussion

GWAS and case-control studies have persistently linked the HMGA2 gene SNPs to human height and cancer risk.23, 25, 31 The genetic importance of these SNPs in hepatoblastoma risk is not clear. In this study, we explored the genetic relevance of potential functional SNPs of the HMGA2 gene to the hepatoblastoma risk. We detected a weak association between HMGA2 SNPs and hepatoblastoma risk.

HMGA2 gene is located in a human chromosome region 12q15. HMGA2 gene is extensively expressed in the embryonic period, but hardly detected in normal adult cells and tissues. In 2013, Lee et al.22 verified that HMGA2 is expressed in all hepatoblastomas and may serve as a marker for the diagnosis of hepatoblastoma. HMGA2 has been shown to promote tumor growth,33 differentiation,34 metastasis,35,36 transformation,37 and DNA damage repair.38 Li et al.39 found that HMGA2 stimulates cell proliferation, aggression, and epithelial-to-mesenchymal transition (EMT) in colon cancer via upregulating the transcription factor Slug. HMGA2-FOXL2 axis could directly regulate malignant progression and EMT of chemoresistant gastric cancer.40 Hodge et al.25 revealed that TC227 allele in the 5′-UTR of the HMGA2 gene alone was closely linked to uterine leiomyoma development in White women. Functional experiments implied that increased HMGA2 expression caused by TC227 allele is causative of elevated risk of uterine leiomyoma development. Liu et al.23 identified HMGA2 rs1563834 as a predictor of long-term survivors in glioblastoma. The first case-control study on the association between HMGA2 SNPs and cancer risk was performed in 2016. The study focuses on cervical cancer in 247 patients and 285 healthy women in Xinjiang Uygur population.42 Among three SNPs in the HMGA2 gene (rs8756, rs11175982, rs1042725) investigated, only minor allele “C” of rs1042725 predisposes to increased risk of cervical cancer.

It is worth pointing out that the HMGA2 gene is a critical member of the MYCN/LIN28B/Let-7/HMGA2 axis, which is implicated in the occurrence of various cancers.35,43–46 Accumulating evidence proves that HMGA2 is a downstream target of the miRNA let–7. Let–7 could bind to multiple target sites in the HMGA2 3′-UTR to promoting its degradation. Indeed, let–7 is often down-regulated in cancers, and line with a high level of HMGA2. Di Fazio et al.47 demonstrated that

Table 2 Stratification Analysis for Association Between HMGA2 Gene Genotypes and Hepatoblastoma Susceptibility

| Variables           | rs968697 (case/control) | OR (95% CI) | P   | AOR (95% CI) | P   | Protective genotypes (case/control) | OR (95% CI) | P   | AOR (95% CI) | P   |
|---------------------|------------------------|-------------|-----|--------------|-----|-------------------------------------|-------------|-----|--------------|-----|
|                     | TT                     | TC/CC       |     |              |     | 0–1                                 |             |     |              |     |
| Age, month          |                        |             |     |              |     | 2–3                                 |             |     |              |     |
| <17                 | 112/329                | 36/130      | 0.81| (0.53–1.25)  | 0.343| 0.82                               | (0.53–1.25) | 0.350| 108/315      | 40/144| 0.81     | (0.54–1.22) | 0.318| 0.81     | (0.54–1.23) | 0.324|
| ≥17                 | 104/414                | 23/145      | 0.63| (0.39–1.03)  | 0.666| 0.63                               | (0.39–1.03) | 0.667| 102/394      | 25/165| 0.59     | (0.36–0.94) | 0.027| 0.59     | (0.37–0.94) | 0.028|
| Gender              |                        |             |     |              |     |                                    |             |     |              |     |
| Female              | 85/292                 | 28/108      | 0.89| (0.55–1.44)  | 0.637| 0.88                               | (0.55–1.43) | 0.613| 83/281       | 30/119| 0.85     | (0.53–1.37) | 0.508| 0.85     | (0.53–1.35) | 0.484|
| Male                | 131/451                | 31/167      | 0.64| (0.42–0.98)  | 0.041| 0.64                               | (0.42–0.98) | 0.040| 127/428      | 35/190| 0.62     | (0.41–0.94) | 0.023| 0.62     | (0.41–0.94) | 0.023|
| Clinical stages     |                        |             |     |              |     |                                    |             |     |              |     |
| I+II                | 115/743                | 27/275      | 0.63| (0.41–0.99)  | 0.043| 0.63                               | (0.41–0.98) | 0.042| 113/709      | 29/309| 0.59     | (0.38–0.90) | 0.016| 0.59     | (0.38–0.90) | 0.016|
| III+IV              | 54/743                 | 17/275      | 0.85| (0.49–1.49)  | 0.573| 0.85                               | (0.48–1.49) | 0.561| 51/709       | 20/309| 0.90     | (0.53–1.54) | 0.698| 0.90     | (0.53–1.53) | 0.687|

Notes: The values were in bold, if the 95% CI excluded 1 or P-value less than 0.05. AAdjusted for age and gender, omitting the corresponding stratify factor. Abbreviations: OR, odds ratio; AOR, adjusted odds ratio; CI, confidence interval.
increased transcription and maturation of the tumor suppressor miRNA hsa-let-7b reduced HMG2A expression in liver cancer cell lines. The maturation of let-7 is negatively regulated by the LIN28B. Nguyen et al. demonstrated that LIN28B likely acts through both let-7-dependent and -independent mechanisms to drive hepatoblastoma tumorigenesis, implicating the LIN28B/let-7 network as an important pathway in hepatoblastoma. Our group has provided evidence of the effects of MYCN/LIN28B/Let-7 gene SNPs on the childhood cancer risk, including hepatoblastoma. Considering the intimately mutual relationship inside MYCN/LIN28B/Let-7 genes and the vital role of individual HMG2A gene in cancers, it is quite biologically feasible to speculate the role of HMG2A SNPs in hepatoblastoma risk. Moreover, it is of great significance that the current study provides the first identification of the role of HMG2A SNPs in hepatoblastoma risk.

Herein, we by far explored the correlation of HMG2A SNPs with the hepatoblastoma susceptibility with the largest study population. Of the three SNPs, we only detected a statistically significant association of SNP rs968697 T>C with hepatoblastoma risk in the additive model. Moreover, we found the children harboring 2–3 favorable genotypes had a lower probability of developing hepatoblastoma. Our data also showed that rs968697 TC/CC and the presence of 2–3 protective genotypes were associated with decreased hepatoblastoma risk, respectively, at some stratification strata. The initiative outcome obtained here implies that HMG2A SNPs may affect hepatoblastoma susceptibility in a weak impact pattern. The SNP rs968697 T>C is located in transcription factor binding sites (TFBS). We speculated such polymorphism may affect the expression of HMG2A, thus affect hepatoblastoma susceptibility.

This study was the first attempt to interrogate the correlation of HMG2A gene SNPs and hepatoblastoma risk. The unprecedentedly large-scale and multi-center based study design are the primary strengths of our study. The study also has some limitations. Firstly, the sample size was relatively moderate because of the low prevalence of hepatoblastoma. Augmentation of the number of hepatoblastoma cases will be further taken to strengthen the statistical power. Secondly, environmental factors that may impact the role of HMG2A gene SNPs were not investigated. Last, the selection bias cannot be excluded as all the subjects were from hospitals. Moreover, the studied population was restricted to the Han Chinese. The exclusion of other ethnicities limits the generalization of the conclusion.

Conclusions
In conclusion, we identified that rs968697 T>C polymorphism was significantly related to hepatoblastoma risk. The characterization of HMG2A gene SNPs sheds light on the role of HMG2A gene SNPs in hepatoblastoma susceptibility and helps to elucidate the etiology of hepatoblastoma. Future larger studies combining genetic and environmental risk factors should be warranted.

Acknowledgments
This study was funded by grants from the National Natural Science Fund of China (No. 81960294 and 81560262), The Basic Applied Study Planning Projects of Yunnan Province (No. 2018FB130), The Joint Special Fund for Basic Research from Yunnan Provincial Science and Technology and Kunming Medical University (No. 2017FE467-149), The High Level Health and Family Planning Technical Personnel Training Projects of Yunnan Province (No. H-201626), Kunming Research Center for Exosome Immunotherapy of Malignant Tumors in Children (No. 2018-SW (R) –5) and the Guangdong Provincial Key Laboratory of Research in Structural Birth Defect Disease (No: 2019B030301004).

Disclosure
The authors have no conflicts of interest to declare.

References
1. Sharma D, Subbarao G, Saxena R. Hepatoblastoma. Semin Diagn Pathol. 2017;34(2):192–200. doi:10.1053/j.semdp.2016.12.015
2. Haas JE, Muczynski KA, Krailo M, et al. Histopathology and prognosis in childhood hepatoblastoma and hepatocarcinoma. Cancer. 1989;64(5):1082–1095. doi:10.1002/(ISSN)1097-0142
3. Musick SR, Babiker HM. Cancer; Hepatoblastoma. Treasure Island, FL; StatPearls; 2019.
4. Czauderna P, Lopez-Terrada D, Hiyama E, Haberle B, Malogolowkin MH, Meyers RL. Hepatoblastoma state of the art: pathology, genetics, risk stratification, and chemotherapy. Curr Opin Pediatr. 2014;26(1):19–28. doi:10.1097/MOP.0000000000000046
5. Haftberg E, Borinstein SC, Alexopoulos SP. Contemporary management of hepatoblastoma. Curr Opin Organ Transplant. 2019;24(2):113–117. doi:10.1097/MOT.0000000000000618
6. Bao PP, Li K, Wu CX, et al. [Recent incidences and trends of childhood malignant solid tumors in Shanghai, 2002–2010]. Zhonghua Er Ke Za Zhi. 2013;51(4):288–294. doi:10.3760/cma.j.issn.0578-1310.2013.04.010
7. Wiwanitkit V. Hepatitis virus B is not a risk factor in hepatoblastoma patients. Asian Pac J Cancer Prev. 2005;6(2):213–214.
8. Spector LG, Birch J. The epidemiology of hepatoblastoma. Pediatr Blood Cancer. 2012;59(5):776–779. doi:10.1002/pbc.v59.5
9. Heck JE, Meyers TJ, Lombardi C, et al. Case-control study of birth characteristics and the risk of hepatoblastoma. Cancer Epidemiol. 2013;37(4):390–395. doi:10.1016/j.canep.2013.03.004
10. Buckley JD, Sather H, Ruicione K, et al. A case-control study of risk factors for hepatoblastoma. A report from the Childrens Cancer Study Group. Cancer. 1989;64(5):1169–1176. doi:10.1002/(ISSN)1097-0142
11. McLaughlin CC, Baptiste MS, Schymura MJ, Nasca PC, Zdebs MS. Maternal and infant birth characteristics and hepatoblastoma. Am J Epidemiol. 2006;163(9):818–828. doi:10.1093/aje/kwj104

12. Spector LG, Johnson KJ, Soler JT, Puonala SE. Perinatal risk factors for hepatoblastoma. Br J Cancer. 2008;98(9):1570–1573. doi:10.1038/sj.bjc.6604335

13. Pakakasama S, Chen TT, Frawley W, Muller C, Douglass EC, Tomlinson GE. Myeloperoxidase promoter polymorphism and risk of hepatoblastoma. Int J Cancer. 2003;106(2):205–207.

14. Pakakasama S, Chen TT, Frawley W, et al. CCND1 polymorphism and age of onset of hepatoblastoma. Oncogene. 2004;23(27):4789–4792. doi:10.1038/sj.onc.1207499

15. Yang T, Li J, Wen Y, et al. LINC00673 rs1655237 C>T polymorphism impacts hepatoblastoma susceptibility in Chinese children. Front Genet. 2019;10:506. doi:10.3389/fgen.2019.00506

16. Yang T, Wen Y, Li J, et al. Association of the TP53 rs1042522 C>G polymorphism and hepatoblastoma risk in Chinese children. J Cancer. 2019;10(15):3444–3449. doi:10.7150/jca.33063

17. Fusco A, Fedele M. Roles of HMG proteins in cancer. Nat Rev Cancer. 2007;7(12):899–910. doi:10.1038/nrc2271

18. West RC, McWhorter ES, Ali A, et al. HMG2 is regulated by LIN28 and BRCA1 in human placental cells. Biol Reprod. 2019;100(1):227–238. doi:10.1093/biolre/ioy183

19. Fedele M, Visoné R, De Martino I, et al. HMG2 induces putative tumorigenesis by enhancing E2F1 activity. Cancer Cell. 2006;9(6):459–471. doi:10.1016/j.ccr.2006.04.024

20. Young AR, Narita M. Oncogenic HMG2: short or small? Genes Dev. 2007;21(9):1005–1009. doi:10.1101/gad.1554707

21. Morishita A, Zaidi MR, Mitoa A, et al. HMG2 is a driver of tumor metastasis. Cancer Res. 2013;73(14):4289–4299. doi:10.1158/0008-5472.CAN-12-3848

22. Weedon MN, Lettge G, Freathy RM, et al. A common variant of HMG2A is associated with adult and childhood height in the general population. Nat Genet. 2007;39(10):1245–1250. doi:10.1038/ng2121

23. Sanna S, Jackson AU, Nagaraja R, et al. Common variants in the GDF5-UQCC region are associated with variation in human height. Nat Genet. 2008;40(2):198–203. doi:10.1038/ng.74

24. Tay Y, Peter S, Rigoutsos I, Barahona P, Ahmed S, Droge P. Insights into the regulation of a common variant of HMG2A associated with human height during embryonic development. Stem Cell Rep. 2009;3(4):328–333. doi:10.1016/j.stem.2009.09.005-8

25. Hodge JC, Cuenco, KT, Huyck KL, et al. Uterine leiomyomata and decreased height: a common HMGA2 predisposition allele. J Clin Lab Anal. 2010;24(5):382–388. doi:10.1002/jcla.20106

26. Zhuo ZJ, Zhang R, Zhang J, et al. Associations between lncRNA ME3 polymorphisms and neuroblastoma risk in Chinese children. Exp Cell Res. 2018;373:1–9. doi:10.1016/j.yexcr.2018.08.018

27. Zhuo ZJ, Liu W, Zhang J, et al. Functional polymorphisms at MEG3 polymorphisms and neuroblastoma risk in Chinese children. Oncogene. 2014;33(27):3528–3537. doi:10.1038/onc.2013.328

28. He J, Qiu LX, Wang MY, et al. Polymorphisms in the XPG gene and age of onset of hepatoblastoma. J Exp Clin Cancer Res. 2009;28:105. doi:10.1186/1756-9966-28-105

29. Li Y, Zhao Z, Yu T, et al. HMG2A induces transcription factor Slug expression to promote epithelial-to-mesenchymal transition and contributes to colon cancer progression. Cancer Lett. 2014;355(1):130–140. doi:10.1016/j.canlet.2014.09.007

30. Dong J, Wang R, Ren G, et al. HMG2A-FOX2L2 axis regulates metastases and epithelial-to-mesenchymal transition of chemoresistant gastric cancer. Clio Cancer Res. 2017;23(13):3461–3473. doi:10.1158/0008-5472.CAN-16-2180

31. Liu Y, Shete S, Erzel CJ, et al. Polymorphisms of LG4, BTBD2, HMG2A, and RTEL1 genes involved in the double-strand break repair pathway predict glioblastoma survival. J Clin Oncol. 2010;28(14):2467–2474. doi:10.1200/JCO.2009.26.6213

32. Yang J, Zhang Z, Guo W, et al. Single nucleotide polymorphisms in miRNA genes are associated with cervical cancer susceptibility in a population from Xinjiang Uygur. Oncotarget. 2016;7(44):71447–71454. doi:10.18632/oncotarget.12121

33. Alam M, Ahmad R, Rajabi H, Kufe D. MUC1-C induces the LIN28B→LET-7→HMG2A axis to regulate self-renewal in NSCLC. Mol Cancer Res. 2015;13(3):449–460. doi:10.1158/1541-7786.MCR-14-0363

34. Balzeau J, Menezes MR, Cao S, Hagan JP. The LIN28/let-7 pathway in cancer. Front Genet. 2017;8:31. doi:10.3389/fgene.2017.00031

35. Busch B, Bley N, Muller S, et al. The oncogenic triangle of HMG2A, LIN28B and IGF2BP1 antagonizes tumor-suppressive actions of the let-7 family. Nucleic Acids Res. 2016;44(8):3845–3864. doi:10.1093/nar/gkw099

36. Guo L, Chen C, Shi M, et al. Polymorphisms of LG4, BTBD2, HMG2A, and miR-200-ZEB1 circuits initiate and maintain oncostatin M-driven epithelial-mesenchymal transition. Oncogene. 2013;32(45):5272–5282. doi:10.1038/onc.2012.573

37. Di Fazio P, Montalbano R, Neureiter D, et al. Downregulation of HMG2A by the pan-deacetylase inhibitor panobinostat is dependent on hsa-let-7b expression in liver cancer cell lines. Exp Cell Res. 2012;318(15):1832–1843. doi:10.1016/j.yexcr.2012.04.018

38. Nguyen LH, Robinton DA, Seligson DT, et al. Lin28b is sufficient to drive liver cancer and necessary for its maintenance in murine models. Cancer Cell. 2014;26(2):248–261. doi:10.1016/j.ccr.2014.06.018

39. Fu W, Liu GC, Zhao Z, et al. The correlation between LIN28B gene potentially functional variants and Wilms tumor susceptibility in Chinese children. J Clin Lab Anal. 2018;32(1):e22200. doi:10.1002/jcla.22200

40. Huang X, Zhao Z, Zhu J, et al. MYCN gene polymorphisms and Wilms tumor susceptibility in Chinese children. J Clin Lab Anal. 2019;33(9):e22988. doi:10.1002/jcla.v33.9

41. Zhou H, Zhao Z, Chen S, et al. Polymorphisms in MYCN gene and neuroblastoma risk in Chinese children: a 3-center case-control study. Cancer Manag Res. 2018;10:1807–1816. doi:10.2147/CMAR.S168515
